Hospitals and Clinics Segment to Dominate APAC Plasma Fractionation Market during 2020–2028      

According to a new market research study on “APAC Plasma Fractionation Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Product, Application, and End User” is expected to reach US$ 9,433.53 million by 2028 from 5,854.65 US$ million in 2021. The market is estimated to grow at a CAGR of 7.1% from 2021 to 2028. The report provides trends prevailing in the APAC plasma fractionation market along with the drivers and restraints pertaining to the market growth. Novel diseases getting treated with use of plasma therapy is the major factor driving the growth of the APAC plasma fractionation market. However, issues associated with non-plasma substitutes options availability hinders the growth of APAC plasma fractionation market.

APAC plasma fractionation market is segmented into product, application, end user, and country. The APAC plasma fractionation market, based on product, has been segmented into immunoglobulin, albumin, coagulation factor concentrates, protease inhibitors, and others. The immunoglobulin segment is likely to hold the largest share of the market in 2021. The APAC plasma fractionation market, based on application is segmented into neurology, immunology, hematology, critical care, pulmonology, and others. In 2021, the Neurology segment is likely to hold the largest share of the market. The APAC plasma fractionation market, based on end user is segmented into hospitals and clinics, clinical research laboratories, academic institutes. In 2021, the hospitals and clinics segment is likely to hold the largest share of the market. Based on country, the APAC plasma fractionation market is segmented into Australia, China, India, Japan, South Korea, and rest of APAC. Japan held the largest market share in 2021.

The supply chain disturbances and the tremendous demand for efficient treatments for the therapy of COVID-19 have put the healthcare research industry in a crucial situation in the APAC region. Preventive measures have been taken to control the spread of this pandemic. The COVID-19 pandemic has broadly affected the economies in the APAC region. Countries such as India, China, Japan, and South Korea were adversely affected by the pandemic. The socioeconomics was severely affected, rising in negative inflation, GDPs, and a regional unemployment surge. Countries such as China, Japan, Singapore, and South Korea are seeing an increased interest in clinical trials. High costs in western countries are also contributing to the flow of medical affairs outsourcing to the APAC region. To expand sales to the Asian market, pharmaceutical companies are becoming aware of new and changing regulatory environments for drugs, devices, and in-vitro diagnostics. New or improved regulations are implemented frequently in Asia, including changes in GMP standards, drug price controls, and medical device regulatory systems. Third-party guidance and advice are required as a part of any acquisition or improvement of current standards. Increasingly, third-party outsourcing service providers are playing a more significant role in supporting the associated market in APAC. However, the market is stabilized compared to the initial phases of the pandemic, owing to the control procedures, awareness among people, availability of vaccinations, and supportive government policies of the business in the related market.   

Bharat Serums and Vaccines Limited (BSV); Bio Products Laboratory Ltd.; CSL Limited; Grifols, S.A.; Kedrion S.p.A; Octapharma AG; PlasmaGen BioSciences Pvt. Ltd.; and SK Plasma are among the leading companies in the APAC plasma fractionation market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com